中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 7
Jul.  2014
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2014  >  30(7): 687-690

Role of transjugular intrahepatic portosystemic shunt in prevention and treatment of variceal bleeding in liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2014.07.031

  • Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Disease, Fourth Military Medical University

  • Received Date: 2014-02-24
  • Published Date: 2014-07-20
    Abstract
  • In patients with liver cirrhosis, variceal bleeding is a common fatal complication of portal hypertension. Varices are present in almost half of patients with cirrhosis at the time of diagnosis. Since transjugular intrahepatic portosystemic shunt (TIPS) was first applied clinically in 1988, the relevant information about TIPS has been continually updated and perfected by lots of clinical trials. The role of TIPS in the prevention and treatment of variceal bleeding in cirrhotic patients with portal hypertension, including primary prevention of variceal bleeding, treatment of acute variceal bleeding, and prevention of rebleeding, is reviewed. TIPS is an effective treatment for variceal bleeding in cirrhotic patients with portal hypertension. Along with the technical development, TIPS will be available for more and more patients and will play an increasingly important role in the prevention and treatment of variceal bleeding among cirrhotic patients with portal hypertension.

     

    • FullText(HTML)
    • References(33)
  • [1] GARCIA-TSAO G, BOSCH J.Management of varices and variceal hemorrhage in cirrhosis[J].N Engl J Med, 2010, 362 (9) :823-832.
    [2]D'AMICO G, PAGLIARO L, BOSCH J.The treatment of portal hypertension:a meta-analytic review[J].Hepatology, 1995, 22 (1) :332-354.
    [3]BOYER TD, HASKAL ZJ.The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension:update 2009[J].Hepatology, 2010, 51 (1) :306.
    [4]WU ZG, ZHOU RM.Clinical follow-up results of patients after transjugular intrahepatic portosystemic shunt[J].J Clin Hepatol, 1999, 15 (2) :118-120. (in Chinese) 吴子刚, 周若美.经颈静脉肝内门体分流术后的临床随访结果[J].临床肝胆病杂志, 1999, 15 (2) :118-120.
    [5]NI JB, ZHANG JW, LI ZL, et al.Short-term efficacy of transjugular intrahepatic portosystemic shunt combined with tissue adhesive embolization in prevention and treatment of esophageal and gastric varices bleeding[J].Chin J Dig, 2010, 30 (11) :842-844. (in Chinese) 倪景斌, 张建武, 李振磊, 等.经颈静脉肝内门体分流术联合组织胶栓塞治疗和预防食管胃底静脉出血近期疗效的研究[J].中华消化杂志, 2010, 30 (11) :842-844.
    [6]GARCIA-TSAO G, SANYAL AJ, GRACE ND, et al.Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis[J].Hepatology, 2007, 46 (3) :922-938.
    [7]BOSCH J, ABRALDES JG, BERZIGOTTI A, et al.Portal hyper-tension and gastrointestinal bleeding[J].Semin Liver Dis, 2008, 28 (1) :3-25.
    [8]BOSCH J.Salvage transjugular intrahepatic portosystemic shunt:is it really life-saving?[J].J Hepatol, 2001, 35 (5) :658-660.
    [9]ESCORSELL A, BANARES R, GARCIA-PAGAN JC, et al.TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis:a randomized controlled trial[J].Hepatology, 2002, 35 (2) :385-392.
    [10]MONESCILLO A, MARTINEZ-LAGARES F, RUIZ-DEL-ARBOL L, et al.Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding[J].Hepatology, 2004, 40 (4) :793-801.
    [11] GARCIA-PAGAN JC, CACA K, BUREAU C, et al.Early use of TIPS in patients with cirrhosis and variceal bleeding[J].N Engl J Med, 2010, 362 (25) :2370-2379.
    [12]GARCIA-PAGAN JC, DI PASCOLI M, CACA K, et al.Use of early-TIPS for high-risk variceal bleeding:results of a postRCT surveillance study[J].J Hepatol, 2013, 58 (1) :45-50.
    [13] AUGUSTIN S, ALTAMIRANO J, GONZALEZ A, et al.Effectiveness of combined pharmacologic and ligation therapy in high-risk patients with acute esophageal variceal bleeding[J].Am J Gastroenterol, 2011, 106 (10) :1787-1795.
    [14]REVERTER E, TANDON P, AUGUSTIN S, et al.A MELDbased model to determine risk of mortality among patients with acute variceal bleeding[J].Gastroenterology, 2014, 146 (2) :412-419.
    [15]CHAU TN, PATCH D, CHAN YW, et al.“Salvage”transjugular intrahepatic portosystemic shunts:gastric fundal compared with esophageal variceal bleeding[J].Gastroenterology, 1998, 114 (5) :981-987.
    [16]BARANGE K, PERON JM, IMANI K, et al.Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices[J].Hepatology, 1999, 30 (5) :1139-1143.
    [17]QI XS, HAN GH, FAN DM.Recent advances in the clinical application of transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension[J].J Intervent Radiol, 2011, 20 (6) :499-504. (in Chinese) 祁兴顺, 韩国宏, 樊代明.经颈内静脉肝内门体分流术临床应用新进展[J].介入放射学杂志, 2011, 20 (6) :499-504.
    [18]SHARARA AI, ROCKEY DC.Gastroesophageal variceal hemorrhage[J].N Engl J Med, 2001, 345 (9) :669-681.
    [19]GONZALEZ R, ZAMORA J, GOMEZ-CAMARERO J, et al.Meta-analysis:Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis[J].Ann Intern Med, 2008, 149 (2) :109-122.
    [20]BURROUGHS AK, VANGELI M.Transjugular intrahepatic portosystemic shunt versus endoscopic therapy:randomized trials for secondary prophylaxis of variceal bleeding:an updated meta-analysis[J].Scand J Gastroenterol, 2002, 37 (3) :249-252.
    [21]ZHENG M, CHEN Y, BAI J, et al.Transjugular intrahepatic portosystemic shunt versus endoscopic therapy in the secondary prophylaxis of variceal rebleeding in cirrhotic patients:meta-analysis update[J].J Clin Gastroenterol, 2008, 42 (5) :507-516.
    [22]LO GH, LIANG HL, CHEN WC, et al.A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt ver-sus cyanoacrylate injection in the prevention of gastric variceal rebleeding[J].Endoscopy, 2007, 39 (8) :679-685.
    [23]ROSEMURGY AS, BLOOMSTON M, CLARK WC, et al.H-graft portacaval shunts versus TIPS:ten-year follow-up of a randomized trial with comparison to predicted survivals[J].Ann Surg, 2005, 241 (2) :238-246.
    [24]HENDERSON JM, BOYER TD, KUTNER MH, et al.Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding:a randomized trial[J].Gastroenterology, 2006, 130 (6) :1643-1651.
    [25]D'AMICO G, LUCA A.TIPS is a cost effective alternative to surgical shunt as a rescue therapy for prevention of recurrent bleeding from esophageal varices[J].J Hepatol, 2008, 48 (3) :387-390.
    [26]LIANG YP, TANG YM, YANG JH, et al.Transjugular intrahepatic portosystemic shunt dysfunction[J].World Chin J Dig, 2013, 21 (4) :336-340. (in Chinese) 梁艳平, 唐映梅, 杨晋辉, 等.TIPS术后支架功能障碍的研究现状[J].世界华人消化杂志, 2013, 21 (4) :336-340.
    [27]PERARNAU JM, LE GOUGE A, NICOLAS C, et al.Covered vs.uncovered stents for transjugular intrahepatic portosystemic shunt:A randomized controlled trial[J].J Hepatol, 2014, 60 (5) :962-968
    [28]LIND CD, MALISCH TW, CHONG WK, et al.Incidence of shunt occlusion or stenosis following transjugular intrahepatic portosystemic shunt placement[J].Gastroenterology, 1994, 106 (5) :1277-1283.
    [29]CAI W, ZHUGE YZ, QIU YD, et al.Risk factors and countermeasures of shunt dysfunction and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J].Chin J Dig Surg, 2013, 12 (11) :850-854. (in Chinese) 蔡炜, 诸葛宇征, 仇毓东, 等.经颈静脉肝内门体分流术后分流道失功和肝性脑病发生的危险因素及预防对策[J].中华消化外科杂志, 2013, 12 (11) :850-854.
    [30]BAI M, QI X, YANG Z, et al.Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients:a systematic review[J].J Gastroenterol Hepatol, 2011, 26 (6) :943-951.
    [31]MALEUX G, HEYE S, VERSLYPE C, et al.Management of transjugular intrahepatic portosystemic shunt induced refractory hepatic encephalopathy with the parallel technique:results of a clinical follow-up study[J].J Vasc Interv Radiol, 2007, 18 (8) :986-992, 993.
    [32]FORAUER AR, MCLEAN GK.Transjugular intrahepatic portosystemic shunt constraining stent for the treatment of refractory postprocedural encephalopathy:a simple design utilizing a Palmaz stent and Wallstent[J].J Vasc Interv Radiol, 1998, 9 (3) :443-446.
    [33]HAN GH, QI XS, FAN DM.Transjugular intrahepatic portosystemic shunt for patients with cirrhosis and acute variceal bleeding:rescue or first-line therapy?[J].J Clin Hepatol, 2011, 27 (3) :239-240. (in Chinese) 韩国宏, 祁兴顺, 樊代明.TIPS治疗肝硬化门脉高压急性静脉曲张出血:救命治疗还是一线治疗?[J].临床肝胆病杂志, 2011, 27 (3) :239-240.
    • Relative Articles

  • Relative Articles

    [1]Li Na, Gou Wei, Cui WeiLi. Efficacy of telbivudine combined with adefovir dipivoxil and pegylated interferon combined with entecavir as antiviral therapy for chronic hepatitis B: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(9): 1714-1716. doi: 10.3969/j.issn.1001-5256.2016.09.015
    [2]Yang DongQiang, Chen Fang, Kang Yi, Ding GangQiang, Xiao ErHui, Peng Zhen, Shang Jia. Genotypes and resistance loci in patients with chronic hepatitis B achieving virologic breakthrough in treatment with lamivudine combined with adefovir after developing drug resistance in treatment with lamivudine alone[J]. Journal of Clinical Hepatology, 2016, 32(3): 480-483. doi: 10.3969/j.issn.1001-5256.2016.03.016
    [3]Zhang Wen, Yu JianGuo, Zhu GuiZhong, Zhao ZhanDong, Wang XiaoWei. Clinical efficacy of entecavir combined with adefovir in chronic hepatitis B patients with high viral load[J]. Journal of Clinical Hepatology, 2014, 30(11): 1169-1172. doi: 10.3969/j.issn.1001-5256.2014.11.019
    [4]Huang MeiJin, Tan HouJi, He YanZhuan, Huang QiWen, Zhou YaoNan, Qiu HaiXian. Forty-eight-week efficacy of adefovir dipivoxil alone versus combined with lamivudine in treatment of lamivudine-resistant HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(7): 636-638. doi: 10.3969/j.issn.1001-5256.2014.07.015
    [5]Ruan BingWei, Lu XiaoJu, Lin YanMing, Chen RongCe, Chen XinZhi, Ceng GuangZhong, Liu YanPing. Evaluation of adverse reactions induced by adefovir dipivoxil in 85 chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2013, 29(2): 104-106.
    [6]Ma YanHong. Clinical effect of initial combination therapy with lamivudine plus adefovir dipivoxil in 48-week treatment of HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(8): 631-632. doi: 10.3969/j.issn.1001-5256.2013.08.020
    [7]Yan HaiMing, Chen JianHua, Ye YiNong, Long Hui, Wang XiangHuai. Clinical effects of lamivudine combined with adefovir dipivoxil and entecavir alone in 48-week treatment of HBeAg-positive chronic hepatitis B:preliminary comparative study[J]. Journal of Clinical Hepatology, 2013, 29(7): 508-511. doi: 1001-5256 (2013) 07-0508-04
    [8]Song MinNing, Huang WenQi, Min Feng, Hong MeiZhu, Fan RongHua, Wu WeiBing, Zhang Li. The efficacy of 3 years adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance[J]. Journal of Clinical Hepatology, 2012, 28(1): 29-32.
    [9]Liu LongGen, Ye ChunYan, Tong XueCheng. Maintenance of negative HBV DNA in patients with chronic hepatitis B during 96 weeks followup with active replacement of Adefovir dipivoxil with Lamivudine[J]. Journal of Clinical Hepatology, 2011, 27(3): 292-294.
    [10]Geng JianZhang, Fan XiaoHong, Lu HaiYing, Li Jing, Tian XiuLan, Xu XiaoYuan. The evaluation of de novo combination of antiviral treatment to hepatitis B patients with decompensated cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(8): 837-839+843.
    [11]Gu QiangYe, Li Qin, Ge XiuLin. Observation of long-term efficacy of different treatment protocol of Adefovir dipivoxil in chronic hepatitis B patients with Lamivudine-resistance[J]. Journal of Clinical Hepatology, 2011, 27(4): 411-413.
    [12]Song MinNing, Zhang Li, Huang WenQi, Min Feng. Treatment of chronic hepatitis B with Adefovir dipivoxil:A 3 years observation of clinical efficacy and drug resistance[J]. Journal of Clinical Hepatology, 2010, 26(1): 22-24.
    [13]Yang YaFang, Yang XiaoPing, Dong JianGuo, Wang ZhiGang, Liu YanPing, Zhao TieJun, Gao Feng.

    Analysis of short-term efficacy of entecavir and adefovir dipivoxil in the treatment of HBeAg-positive chronic hepatitis B

    [J]. Journal of Clinical Hepatology, 2010, 26(3): 326-327.
    [14]Zhu FeiYan. The clinical effect Adefovir dipivoxil in Lamivudine resistant HBeAg positive chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2010, 26(5): 517-518.
    [19]Cao TianGao, Li JingNan, Shi YunZhen, Li ChaoXia. The clinical study of foscarnet sodium combined with adefovir dipivoxil for lamivudine-resistant patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2008, 24(4): 248-250.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(11)

    1. 肖春桃，李贤秋，甘佩灵，潘潇，周贤. 基于倾向性评分匹配分析门静脉血栓对肝硬化患者预后的影响. 临床肝胆病杂志. 2021(08): 1829-1835 . 本站查看
    2. 王彤，牛焕章，杜廷伟，魏乐群. 乙型肝炎肝硬化患者门静脉血栓发生的影响因素及抗凝治疗效果研究. 深圳中西医结合杂志. 2021(17): 134-136 .
    3. 姜炅，袁佳，史海涛，戴社教. 血清ALT、AST联合NFS评分对非酒精性脂肪性肝硬化患者食管胃底静脉曲张严重程度的评估价值. 中西医结合肝病杂志. 2020(04): 314-317 .
    4. 李英，高磊，胡扬喜，胡德升. 低分子肝素钙联合右旋糖酐在肝硬化门静脉高压症术后静脉血栓形成预防中的应用. 肝脏. 2019(07): 788-790 .
    5. 吕靖，董思思，顾宏图，赵长青，刘成海. 肝硬化并发门静脉血栓的危险因素及中医证候特点. 临床肝胆病杂志. 2019(10): 2210-2213 . 本站查看
    6. 陈仙艳. 肝硬化合并上消化道出血患者门静脉血栓形成危险因素分析与护理. 护理实践与研究. 2019(18): 13-15 .
    7. 牟思玉，杨哲，吴力群，邱轩，郭珈铭. 肝硬化门静脉高压脾切除术后门静脉血栓形成的预测因素分析. 临床肝胆病杂志. 2018(01): 106-111 . 本站查看
    8. 张津瑜，陈文显，沈华，王雁，张国雷，慎华平，吴万波，魏云海. 大鼠门静脉系统血栓形成模型的建立和观察. 中国普通外科杂志. 2018(06): 724-731 .
    9. 邢文立，李谦. 重症监护病房肝病患者的血栓预防与出血控制. 临床肝胆病杂志. 2018(10): 2237-2240 . 本站查看
    10. 李志州，向俊峰，周威，唐亮. 探讨门脉高压及外伤性脾破裂行脾切除术后血小板升高及门静脉血栓形成情况. 肝胆外科杂志. 2018(04): 280-282 .
    11. 王士浩，张宏伟. 肝硬化合并门静脉血栓形成危险因素的病例对照研究. 中国中西医结合消化杂志. 2017(11): 867-870 .

    Other cited types(12)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 15.1 %FULLTEXT: 15.1 %META: 80.5 %META: 80.5 %PDF: 4.4 %PDF: 4.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.7 %其他: 4.7 %其他: 0.6 %其他: 0.6 %Bengaluru: 0.2 %Bengaluru: 0.2 %China: 0.7 %China: 0.7 %India: 0.2 %India: 0.2 %Japan: 0.1 %Japan: 0.1 %Kennedy Town: 0.2 %Kennedy Town: 0.2 %North Point: 0.2 %North Point: 0.2 %Seattle: 0.1 %Seattle: 0.1 %United States: 0.2 %United States: 0.2 %[]: 0.4 %[]: 0.4 %上海: 9.5 %上海: 9.5 %东莞: 0.6 %东莞: 0.6 %中卫: 0.1 %中卫: 0.1 %佛山: 0.2 %佛山: 0.2 %佳木斯: 0.1 %佳木斯: 0.1 %北京: 9.3 %北京: 9.3 %南京: 0.6 %南京: 0.6 %南宁: 0.1 %南宁: 0.1 %南阳: 0.1 %南阳: 0.1 %印度泰米尔纳德: 0.1 %印度泰米尔纳德: 0.1 %厦门: 0.1 %厦门: 0.1 %台北: 0.1 %台北: 0.1 %台州: 0.1 %台州: 0.1 %合肥: 0.3 %合肥: 0.3 %周口: 0.1 %周口: 0.1 %哈尔滨: 0.1 %哈尔滨: 0.1 %唐山: 0.1 %唐山: 0.1 %喀什: 0.2 %喀什: 0.2 %圣地亚哥: 0.1 %圣地亚哥: 0.1 %大连: 0.4 %大连: 0.4 %天津: 0.4 %天津: 0.4 %常德: 0.1 %常德: 0.1 %广州: 1.0 %广州: 1.0 %张家口: 1.4 %张家口: 1.4 %成都: 0.2 %成都: 0.2 %扬州: 0.3 %扬州: 0.3 %无锡: 0.2 %无锡: 0.2 %晋城: 0.2 %晋城: 0.2 %杭州: 0.5 %杭州: 0.5 %柳州: 0.1 %柳州: 0.1 %武汉: 0.3 %武汉: 0.3 %水牛城: 0.1 %水牛城: 0.1 %永州: 0.2 %永州: 0.2 %沈阳: 0.2 %沈阳: 0.2 %沈阳市和平区: 0.1 %沈阳市和平区: 0.1 %泰安: 0.2 %泰安: 0.2 %泰州: 0.3 %泰州: 0.3 %洛阳: 0.4 %洛阳: 0.4 %济南: 0.6 %济南: 0.6 %海得拉巴: 0.1 %海得拉巴: 0.1 %深圳: 0.5 %深圳: 0.5 %渭南: 0.1 %渭南: 0.1 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.1 %漯河: 0.1 %百色: 0.2 %百色: 0.2 %眉山: 0.1 %眉山: 0.1 %石嘴山: 0.1 %石嘴山: 0.1 %石家庄: 0.1 %石家庄: 0.1 %秦皇岛: 0.2 %秦皇岛: 0.2 %米兰: 0.1 %米兰: 0.1 %美国伊利诺斯芝加哥: 0.1 %美国伊利诺斯芝加哥: 0.1 %聊城市东昌府区: 0.1 %聊城市东昌府区: 0.1 %芒廷维尤: 38.2 %芒廷维尤: 38.2 %芝加哥: 0.3 %芝加哥: 0.3 %苏州: 0.1 %苏州: 0.1 %莫斯科: 0.6 %莫斯科: 0.6 %莱芜: 0.1 %莱芜: 0.1 %菏泽: 0.2 %菏泽: 0.2 %萍乡: 0.1 %萍乡: 0.1 %葵涌: 0.1 %葵涌: 0.1 %衢州: 0.1 %衢州: 0.1 %西宁: 14.2 %西宁: 14.2 %西安: 2.2 %西安: 2.2 %西安市新城区: 0.1 %西安市新城区: 0.1 %许昌: 0.1 %许昌: 0.1 %诺沃克: 0.1 %诺沃克: 0.1 %贵阳: 0.1 %贵阳: 0.1 %赤峰: 0.1 %赤峰: 0.1 %运城: 1.0 %运城: 1.0 %郑州: 0.2 %郑州: 0.2 %重庆: 0.1 %重庆: 0.1 %长春: 0.6 %长春: 0.6 %长沙: 2.2 %长沙: 2.2 %长治: 0.1 %长治: 0.1 %雅安: 1.0 %雅安: 1.0 %青岛: 0.4 %青岛: 0.4 %香港: 0.2 %香港: 0.2 %驻马店: 0.1 %驻马店: 0.1 %黄冈: 0.2 %黄冈: 0.2 %其他其他BengaluruChinaIndiaJapanKennedy TownNorth PointSeattleUnited States[]上海东莞中卫佛山佳木斯北京南京南宁南阳印度泰米尔纳德厦门台北台州合肥周口哈尔滨唐山喀什圣地亚哥大连天津常德广州张家口成都扬州无锡晋城杭州柳州武汉水牛城永州沈阳沈阳市和平区泰安泰州洛阳济南海得拉巴深圳渭南湘潭漯河百色眉山石嘴山石家庄秦皇岛米兰美国伊利诺斯芝加哥聊城市东昌府区芒廷维尤芝加哥苏州莫斯科莱芜菏泽萍乡葵涌衢州西宁西安西安市新城区许昌诺沃克贵阳赤峰运城郑州重庆长春长沙长治雅安青岛香港驻马店黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2451) PDF downloads(536) Cited by(23)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2462]YesterdayPV[4905]TodayIP[103]TodayPV[185]Online[46]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return